483
Shanghai Ambiopharm Inc.Shanghai Ambiopharm Inc. – FDA 483, May 22, 2026
Record Details
Shanghai AmbioPharm, Inc., a drug manufacturer, was cited for significant deficiencies during an FDA inspection. Observations included a lack of written quality control procedures and quality agreements with third-party testers, unqualified and poorly managed manufacturing equipment, and incomplete master production and batch records. These issues indicate a systemic failure in maintaining adequate control over manufacturing processes and quality assurance.
View Company Profile
ID · e7b9fe4d-7205-46e2-aa43-cb2362aea1e2
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.